Quote this publication Share Print

ACTOSOLV UROKINASE

-
Opinions on drugs - Posted on Nov 03 2009

Reason for request

Change in the conditions of inclusion. Inclusion on the list of medicines approved for use by hospitals in the extension of indication “Restoration of patency of intravascular catheters (central venous catheters and dialysis catheters), blocked by a forming or recently formed thrombus”.

-


Actual benefit

Important

The actual benefit of ACTOSOLV UROKINASE is substantial.


Improvement in actual benefit

III (modéré)

In the indication “restoration of patency of intravascular catheters (central venous catheters and dialysis catheters), blocked by forming or recently formed fibrin clots” the proprietary products ACTOSOLV UROKINASE 100,000 and 600,000 IU provides a moderate improvement in actual benefit (IAB III) during their therapeutic use.


Contact Us

Évaluation des médicaments